NCT03759093 2023-09-06
CURATE.AI Optimized Modulation for Multiple Myeloma
National University Hospital, Singapore
Phase 2/3 Unknown
Clinical Trials
13 trialsNCT04753177 2021-02-15
The Neoadjuvant Combined Hormone Therapy in Premenopausal Women With Locally Advanced ER+/HER2- Breast Cancer
Saint Petersburg State Budgetary Healthcare Institution, City Clinical Oncology Dispensary
Phase 2/3 Unknown
NCT03385096 2020-02-25
Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT
Nanfang Hospital, Southern Medical University
Phase 2/3 Unknown
NCT04123392 2019-10-10
Decitabine + BUCY vs BUCY Conditioning Regimen for TP53+ Myeloid Tumors Undergoing Allo-HSCT
Nanfang Hospital, Southern Medical University
Phase 2/3 Unknown
NCT04098653 2019-09-23
Decitabine + BUCY vs BUCY Conditioning Regimen for Myeloid Tumors Undergoing Allo-HSCT
Nanfang Hospital, Southern Medical University
Phase 2/3 Unknown
NCT01907529 2019-08-09
TENDENCY
Hebei Medical University Fourth Hospital
Phase 2/3 Unknown
NCT03564704 2018-06-21
Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL
Nanfang Hospital, Southern Medical University
Phase 2/3 Unknown
NCT03553238 2018-06-12
Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL
Nanfang Hospital, Southern Medical University
Phase 2/3 Unknown
NCT03349177 2017-11-21
Pathological Complete Response Rate in Locally Advanced Breast Cancer With FEC, EC-T, or TC as Neoadjuvant Chemotherapy
Shandong Cancer Hospital and Institute
Phase 2/3 Unknown
NCT03229616 2017-10-12
BUCY+VP-16 vs BUCY Conditioning Regimen for DLBCL Undergoing Auto-HSCT
Nanfang Hospital, Southern Medical University
Phase 2/3 Unknown
NCT02871869 2017-07-17
Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma
Xinjiang Medical University
Phase 2/3 Unknown
NCT02270307 2014-10-21
MSC-CY
National Research Center for Hematology, Russia
Phase 2/3 Unknown
NCT00525642 2007-09-06
Study of Suitable Schedule of Docetaxel,Anthracycline and Cyclophosphamide in Adjuvant Therapy of Beast Cancer
Fudan University
Phase 2/3 Unknown